Stonebridge Capital Management Inc. Acquires 100 Shares of Johnson & Johnson (NYSE:JNJ)

Stonebridge Capital Management Inc. raised its holdings in Johnson & Johnson (NYSE:JNJ) by 0.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,810 shares of the company’s stock after buying an additional 100 shares during the period. Johnson & Johnson comprises about 3.8% of Stonebridge Capital Management Inc.’s holdings, making the stock its 5th largest position. Stonebridge Capital Management Inc.’s holdings in Johnson & Johnson were worth $9,994,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of JNJ. Means Investment CO. Inc. grew its holdings in shares of Johnson & Johnson by 1.1% during the first quarter. Means Investment CO. Inc. now owns 29,294 shares of the company’s stock worth $4,814,000 after buying an additional 318 shares during the last quarter. Security National Bank grew its holdings in shares of Johnson & Johnson by 6.1% during the first quarter. Security National Bank now owns 25,308 shares of the company’s stock worth $4,159,000 after buying an additional 1,449 shares during the last quarter. Jacobs & Co. CA grew its holdings in shares of Johnson & Johnson by 1.0% during the first quarter. Jacobs & Co. CA now owns 60,166 shares of the company’s stock worth $9,888,000 after buying an additional 571 shares during the last quarter. Modus Advisors LLC grew its holdings in shares of Johnson & Johnson by 3.8% during the first quarter. Modus Advisors LLC now owns 10,168 shares of the company’s stock worth $1,671,000 after buying an additional 373 shares during the last quarter. Finally, FC Advisory LLC boosted its holdings in Johnson & Johnson by 4.4% in the 1st quarter. FC Advisory LLC now owns 2,610 shares of the company’s stock valued at $429,000 after purchasing an additional 110 shares in the last quarter. Institutional investors own 67.25% of the company’s stock.

JNJ traded down $0.05 during trading on Thursday, hitting $163.56. The company’s stock had a trading volume of 76,089 shares, compared to its average volume of 8,177,090. The firm’s 50 day moving average price is $161.06 and its 200-day moving average price is $154.38. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.48 and a quick ratio of 1.24. The stock has a market cap of $430.61 billion, a PE ratio of 25.76, a PEG ratio of 3.06 and a beta of 0.70. Johnson & Johnson has a twelve month low of $133.65 and a twelve month high of $173.65.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Monday, January 25th. The company reported $1.86 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.82 by $0.04. The company had revenue of $22.50 million during the quarter, compared to the consensus estimate of $21.62 billion. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. Johnson & Johnson’s revenue was up 8.7% on a year-over-year basis. During the same period in the previous year, the firm posted $1.88 EPS. Equities analysts anticipate that Johnson & Johnson will post 7.99 earnings per share for the current year.

A number of equities research analysts have weighed in on JNJ shares. Cantor Fitzgerald lifted their price objective on Johnson & Johnson from $180.00 to $200.00 and gave the company an “overweight” rating in a report on Tuesday, January 26th. SVB Leerink boosted their price target on Johnson & Johnson from $180.00 to $200.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 27th. Credit Suisse Group boosted their price target on Johnson & Johnson from $168.00 to $193.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 27th. Wells Fargo & Company boosted their price target on Johnson & Johnson from $175.00 to $190.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 27th. Finally, JPMorgan Chase & Co. boosted their price target on Johnson & Johnson from $157.00 to $175.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 27th. One analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have given a buy rating to the company’s stock. Johnson & Johnson presently has an average rating of “Buy” and an average target price of $178.60.

Johnson & Johnson Profile

Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Recommended Story: How dollar cost averaging works

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.